BACKGROUND: The aims of the study were to identify the significance of interleukin (IL)-6 production and to determine whether IL-6 production influences long-term survival in patients with non-small-cell lung cancer (NSCLC). METHOD: A series of 90 patients with NSCLC who underwent surgery between 2005 and 2007 was analyzed. Preoperative serum IL-6 was measured, and tumor samples were immunohistochemically stained for IL-6. RESULTS: Serum IL-6 levels were elevated in 43 of 90 cases (47.7%), and 23 (25.5%) of 90 cases stained positively for IL-6 (P = .00265). The prognosis of patients with NSCLC who had positive immunohistochemical staining was significantly worse than that for those who had negative staining, by univariate analysis (P = .0027). Multivariate analysis indicated that tumor size, postoperative stage, and overexpression of IL-6 were independent prognostic factors. CONCLUSIONS: The expression of IL-6 in tumor correlated with the concentration of serum IL-6, tumor progression, and overall survival in patients with NSCLC.
BACKGROUND: The aims of the study were to identify the significance of interleukin (IL)-6 production and to determine whether IL-6 production influences long-term survival in patients with non-small-cell lung cancer (NSCLC). METHOD: A series of 90 patients with NSCLC who underwent surgery between 2005 and 2007 was analyzed. Preoperative serum IL-6 was measured, and tumor samples were immunohistochemically stained for IL-6. RESULTS: Serum IL-6 levels were elevated in 43 of 90 cases (47.7%), and 23 (25.5%) of 90 cases stained positively for IL-6 (P = .00265). The prognosis of patients with NSCLC who had positive immunohistochemical staining was significantly worse than that for those who had negative staining, by univariate analysis (P = .0027). Multivariate analysis indicated that tumor size, postoperative stage, and overexpression of IL-6 were independent prognostic factors. CONCLUSIONS: The expression of IL-6 in tumor correlated with the concentration of serum IL-6, tumor progression, and overall survival in patients with NSCLC.
Authors: Timothy D Clay; Prudence A Russell; Hongdo Do; Vijaya Sundararajan; Matthew Conron; Gavin M Wright; Benjamin Solomon; Alexander Dobrovic; Sue-Anne McLachlan; Melissa M Moore Journal: Med Oncol Date: 2017-09-06 Impact factor: 3.064
Authors: T Fleitas; V Martínez-Sales; V Vila; E Reganon; D Mesado; M Martín; J Gómez-Codina; J Montalar; G Reynés Journal: Clin Transl Oncol Date: 2013-03-05 Impact factor: 3.405
Authors: D Ross Camidge; Eamon M Berge; Robert C Doebele; Marc S Ballas; Thierry Jahan; Missak Haigentz; David Hoffman; James Spicer; Howard West; Pablo Lee; Ling Yang; Adarsh Joshi; Ling Gao; Sergey Yurasov; Alain Mita Journal: J Thorac Oncol Date: 2014-10 Impact factor: 15.609